Extract
Asthma exacerbations have major impacts on patient quality of life and contribute to >80% of direct medical expenditures for asthma [1, 2]. Many asthma patients are helped by treatments targeting inflammation pathways, with efficacy evaluated by monitoring symptoms and exacerbations. The fractional concentration of exhaled nitric oxide (FENO) has been proposed as an objective measure of treatment efficacy in reducing eosinophilic, especially type 2 (T2)-high inflammation, a key mechanism underlying exacerbations [3]. Assessment of FENO at a conventional expiratory flow rate of 50 mL·s−1 (FENO50) has been standardised [4, 5] and is now recommended as providing complementary information for asthma diagnosis [6] and treatment [7].
Abstract
Alveolar inflammation, as assessed by partitioned exhaled nitric oxide, appears to provide promising insights into small airway disease relevant to asthma exacerbation https://bit.ly/38KqyCk
Footnotes
Conflict of interest: S.P. Eckel, E. Garcia and F.D. Gilliland all report NIH grants paid to their institution in the past 36 months, and no other conflicts of interest.
- Received April 21, 2022.
- Accepted April 24, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org